Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Peptide receptor radionuclide therapy
7 evidence topics · 7 sources
PRRT for hypoglycemia in metastatic insulinoma: ENETS 2023 guidance
PRRT: requirement for somatostatin receptor expression, symptomatic response, and serious adverse effects
“It is imperative to demonstrate expression of SSTR on the tumors using pretreatment 68Ga DOTANOC / DOTATOC / DOTATATE PET/CT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Favorable symptomatic and biochemical responses using PRRT with 177Lu-DOTATATE have been obtained in small patient series with functioning metastatic gastrointestinal tract and pancreas NEN like metastatic insulinomas, even when there was no visible tumor regression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, rare (2%) but serious side effects include severe and irreversible bone marrow disease (pancytopenia, acute myelogenous leukemia, and myelodysplastic syndrome)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PRRT in metastatic insulinoma: Basel single-center long-term series
“In the long term, a total of 21 of 26 patients (81%) demonstrated improvement during the observation period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average time of benefit (improvement of hypoglycemia) was 17.2 mo (range, 0–70.2 mo), with no differences between tumor grade 1, 2, or 3” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 58% of patients (15/26), a reduction of antihypoglycemic medication was achieved after PRRT during the observation period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median OS was 19.7 mo (95% CI, 6.5–32.9 mo)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 26 patients, 5 (19%) experienced transient hypoglycemia after injection of [90Y]Y-DOTATOC/[177Lu]Lu-DOTATOC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lutetium Lu 177 dotatate in malignant insulinoma: two Australian centers
“Of 15 patients (seven female; median age 60, range 26-82) treated for intractable hypoglycaemia, WHO grade (G) was known in 12 patients (three G1, six G2 and three G3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Resolution of hypoglycaemia was observed in 14/15 (93%) patients after a median of 2.5 months (range 0.2-23.5), but recurred in 7/14 cases after a median of 17.7 months (range 7.6-48.3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In all seven cases, PRRT re-treatment was successful.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Side-effects included G3/4 myelosuppression in 4/15 patients and hypoglycaemia flare (hospitalisation >48 h) in 7/15 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
PRRT in malignant insulinoma: hypoglycemia control and overall survival, Mayo Clinic cohort
“PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PRRT demonstrated a median OS of 49.73 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lutetium Lu 177 dotatate in functioning pancreatic neuroendocrine tumors including 14 insulinomas
“Thirty-four patients with a metastatic functioning pNET (European Neuroendocrine Tumor Society grade 1 or 2) were included: 14 insulinomas, 5 VIPomas, 7 gastrinomas, and 8 glucagonomas.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subacute hematological toxicity, grade 3 or 4 occurred in 4 patients (12%) and a hormonal crisis in 3 patients (9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“71% of patients with uncontrolled symptoms had a reduction of symptoms and a more than 80% decrease of circulating hormone levels was measured during follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote